Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.09.2023 | Case report

Adalimumab/canakinumab

Paradoxical pyoderma gangrenosum and flare of pyoderma angrenosum: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Romagnuolo M, et al. Pyoderma gangrenosum following anti-TNF therapy in chronic recurrent multifocal osteomyelitis: drug reaction or cutaneous manifestation of the disease? A critical review on the topic with an emblematic case report. Frontiers in Medicine 10: 31 May 2023. Available from: URL: http://doi.org/10.3389/fmed.2023.1197273 Romagnuolo M, et al. Pyoderma gangrenosum following anti-TNF therapy in chronic recurrent multifocal osteomyelitis: drug reaction or cutaneous manifestation of the disease? A critical review on the topic with an emblematic case report. Frontiers in Medicine 10: 31 May 2023. Available from: URL: http://​doi.​org/​10.​3389/​fmed.​2023.​1197273
Metadaten
Titel
Adalimumab/canakinumab
Paradoxical pyoderma gangrenosum and flare of pyoderma angrenosum: case report
Publikationsdatum
01.09.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-45748-2

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Multiple drugs

Case report

Multiple drugs

Case report

Aflibercept

Case report

Nivolumab